Fibrosis Research in Systemic Sclerosis (SSc)

Deadline for manuscript submissions: 28 March 2025.

Guest Editors (2)

Carol M.  Artlett
Prof. Carol M. Artlett 
Department of Microbiology & Immunology, College of Medicine, Drexel University, Philadelphia, 19129, PA, USA
Interests: Inflammasome Signaling; IL-1 Mediated Fibrosis; Collagen Export from the Endoplasmic Reticulum; miR-155; Small Molecule Therapeutic Development
Clara  Dees
Dr. Clara Dees 
Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Department of Internal Medicine 3—Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany
Interests: Cell Signaling; Signal Transduction; Extracellular Matrix Biology; Cell Culture; Rheumatology; Fibrosis; Fibroblast; Systemic Sclerosis

Topic Collection Information

Systemic sclerosis (SSc, scleroderma), is an autoimmune disease characterized by inflammation with vascular abnormalities. A major hallmark of SSc is the excessive accumulation of extracellular matrix (ECM) in the skin and visceral organs, leading to morbidity and mortality. The ECM products are released from fibroblasts activated by cytokines, growth factors, and/or epigenetic changes in the genome. Currently, there are no truly effective treatment options for fibrosis.

In this special issue of Fibrosis, we invite you to contribute original research articles, reviews, case reports, or expert perspectives/opinions on all aspects related to "Fibrosis Research in Systemic Sclerosis (SSc)".

Relevant topics related to SSc fibrosis might be:
  • Cellular and molecular mechanisms governing fibroblast activation
  • Recent advances in experimental models of fibrosis (in vitro or in vivo models)
  • SSc-related organ fibrosis (e.g. lung, gastrointestinal, cardiac, renal, skin)
  • Genetics/epigenetics mechanisms driving fibrosis in SSc
  • Translational studies or therapies targeting fibrogenesis

Published Papers (0 papers)

TOP